These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
471 related articles for article (PubMed ID: 33319660)
1. Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies. Borah P; Deb PK; Venugopala KN; Al-Shar'i NA; Singh V; Deka S; Srivastava A; Tiwari V; Mailavaram RP Curr Top Med Chem; 2021; 21(6):547-570. PubMed ID: 33319660 [TBL] [Abstract][Full Text] [Related]
2. Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Miotto P; Zhang Y; Cirillo DM; Yam WC Respirology; 2018 Dec; 23(12):1098-1113. PubMed ID: 30189463 [TBL] [Abstract][Full Text] [Related]
3. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance. Lohrasbi V; Talebi M; Bialvaei AZ; Fattorini L; Drancourt M; Heidary M; Darban-Sarokhalil D Tuberculosis (Edinb); 2018 Mar; 109():17-27. PubMed ID: 29559117 [TBL] [Abstract][Full Text] [Related]
4. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea. Yang JS; Kim KJ; Choi H; Lee SH Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700 [TBL] [Abstract][Full Text] [Related]
5. Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study. Guglielmetti L; Veziris N; Aubry A; Brossier F; Bernard C; Sougakoff W; Jarlier V; Robert J Int J Tuberc Lung Dis; 2018 Jan; 22(1):54-59. PubMed ID: 29297426 [TBL] [Abstract][Full Text] [Related]
6. Drug Resistance Characteristics of Wu X; Yang J; Tan G; Liu H; Liu Y; Guo Y; Gao R; Wan B; Yu F Front Cell Infect Microbiol; 2019; 9():345. PubMed ID: 31828045 [No Abstract] [Full Text] [Related]
7. Extensively drug-resistant tuberculosis in Myanmar: burden and mutations causing second-line drug resistance. Ei PW; Aung WW; Nyunt WW; Swe TL; Htwe MM; Win SM; Aung ST; Chang CL; Lee HY; Lee JS Int J Tuberc Lung Dis; 2018 Jan; 22(1):47-53. PubMed ID: 29297425 [TBL] [Abstract][Full Text] [Related]
8. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909 [TBL] [Abstract][Full Text] [Related]
9. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates. Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332 [TBL] [Abstract][Full Text] [Related]
10. Recent updates on drug resistance in Mycobacterium tuberculosis. Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643 [TBL] [Abstract][Full Text] [Related]
11. Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779 [TBL] [Abstract][Full Text] [Related]
12. Review on emergence of drug-resistant tuberculosis (MDR & XDR-TB) and its molecular diagnosis in Ethiopia. Saravanan M; Niguse S; Abdulkader M; Tsegay E; Hailekiros H; Gebrekidan A; Araya T; Pugazhendhi A Microb Pathog; 2018 Apr; 117():237-242. PubMed ID: 29486274 [TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the QuantaMatrix Multiplexed Assay Platform for Molecular Diagnosis of Multidrug- and Extensively Drug-Resistant Tuberculosis Using Clinical Strains Isolated in Myanmar. Chang Y; Kim S; Kim Y; Ei PW; Hwang D; Lee J; Chang CL; Lee H Ann Lab Med; 2020 Mar; 40(2):142-147. PubMed ID: 31650730 [TBL] [Abstract][Full Text] [Related]
15. Mycobacterial interspersed repetitive unit typing and mutational profile for multidrug-resistant and extensively drug-resistant tuberculosis surveillance in Portugal: a 3-year period overview. Silva C; Perdigão J; Jordão L; Portugal I Int J Antimicrob Agents; 2014 Dec; 44(6):546-51. PubMed ID: 25270633 [TBL] [Abstract][Full Text] [Related]
16. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. Amaral L; Martins M; Viveiros M; Molnar J; Kristiansen JE Curr Drug Targets; 2008 Sep; 9(9):816-9. PubMed ID: 18781927 [TBL] [Abstract][Full Text] [Related]
17. DFT based QSAR/QSPR models in the development of novel anti-tuberculosis drugs targeting Mycobacterium tuberculosis. Rajkhowa S; Deka RC Curr Pharm Des; 2014; 20(27):4455-73. PubMed ID: 24245759 [TBL] [Abstract][Full Text] [Related]
18. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767 [TBL] [Abstract][Full Text] [Related]
19. Management of drug resistantTB in patients with HIV co-infection. Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945 [TBL] [Abstract][Full Text] [Related]
20. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Velayati AA; Masjedi MR; Farnia P; Tabarsi P; Ghanavi J; ZiaZarifi AH; Hoffner SE Chest; 2009 Aug; 136(2):420-425. PubMed ID: 19349380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]